Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1977-11-30
|
| pubmed:abstractText |
Treatment of 16 SLE patients with levamisole resulted in significant reduction of a variety of clinical parameters of the disease. Clinical improvement was both subjective and objective. Thus, levamisole may represent a possible alternative or adjunctive approach to SLE therapy. Although proper assessment of its actual quantitative importance in the treatment of Lupus must await large scale studies under double-blind conditions, nevertheless, these preliminary results are very encouraging.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0003-4738
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
227-36
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:71868-Antibodies, Antinuclear,
pubmed-meshheading:71868-B-Lymphocytes,
pubmed-meshheading:71868-Follow-Up Studies,
pubmed-meshheading:71868-Humans,
pubmed-meshheading:71868-Levamisole,
pubmed-meshheading:71868-Lupus Erythematosus, Systemic,
pubmed-meshheading:71868-Morbidity,
pubmed-meshheading:71868-Neutrophils,
pubmed-meshheading:71868-Prednisone,
pubmed-meshheading:71868-Rosette Formation,
pubmed-meshheading:71868-T-Lymphocytes
|
| pubmed:year |
1977
|
| pubmed:articleTitle |
Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: a follow-up report of 16 patients under treatment for a minimum period of four months.
|
| pubmed:publicationType |
Journal Article
|